{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:23:23Z","timestamp":1790774603131,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004599","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ejca.2022.03.034","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T23:39:51Z","timestamp":1651189191000},"page":"42-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer"],"prefix":"10.1016","volume":"169","author":[{"given":"Sehhoon","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3897-6127","authenticated-orcid":false,"given":"Jae Myoung","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-La","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Ah","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0865-2236","authenticated-orcid":false,"given":"Kyunga","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Ae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Seok","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Mu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejca.2022.03.034_bib1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2022.03.034_bib2","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1470-2045(17)30318-2","article-title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","volume":"18","author":"Faivre-Finn","year":"2017","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2022.03.034_bib3","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/annonc\/mdt140","article-title":"Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer","volume":"24","author":"Sun","year":"2013","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2022.03.034_bib4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.annonc.2021.01.071","article-title":"Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331","volume":"32","author":"Spigel","year":"2021","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2022.03.034_bib5","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jtho.2019.12.109","article-title":"Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies","volume":"15","author":"Chung","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"23","key":"10.1016\/j.ejca.2022.03.034_bib6","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.ejca.2022.03.034_bib7","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.ejca.2022.03.034_bib8","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ejca.2022.03.034_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143497","article-title":"Clinical outcomes of pencil beam scanning proton therapy in locally advanced non-small cell lung cancer: propensity score analysis","volume":"13","author":"Kim","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.ejca.2022.03.034_bib10","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.4143\/crt.2018.415","volume":"51","author":"Chung","year":"2019","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ejca.2022.03.034_bib11","series-title":"CC. AJCC Cancer Staging Manual","author":"Edge","year":"2009"},{"issue":"4","key":"10.1016\/j.ejca.2022.03.034_bib12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM199901283400403","article-title":"Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide","volume":"340","author":"Turrisi","year":"1999","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2022.03.034_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cllc.2018.08.015","article-title":"Radiation dose and fractionation for limited-stage small-cell lung cancer: survey of US radiation oncologists on practice patterns","volume":"20","author":"Farrell","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ejca.2022.03.034_bib14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.lungcan.2019.08.007","article-title":"Current management of limited-stage SCLC and CONVERT trial impact: results of the EORTC Lung Cancer Group survey","volume":"136","author":"Levy","year":"2019","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2022.03.034_bib15","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.ijrobp.2012.10.016","article-title":"Penetration of recommended procedures for lung cancer staging and management in the United States over 10 Years: a quality research in radiation Oncology survey","volume":"85","author":"Komaki","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2022.03.034_bib16","series-title":"NCCN Clinical Practice Guidelines in Oncology. Small Cell Lung Cancer","year":"2022"},{"issue":"12","key":"10.1016\/j.ejca.2022.03.034_bib17","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.jtho.2020.08.022","article-title":"Phase 1\/2 trial of pembrolizumab and concurrent chemoradiation therapy for limited-stage SCLC","volume":"15","author":"Welsh","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2022.03.034_bib18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.annonc.2021.09.011","article-title":"Consolidation nivolumab and ipilimumab versus observation in limited-disease small cell lung cancer after chemo-radiotherapy \u2013 results from the randomised phase II ETOP\/IFCT 4-12 STIMULI trial","volume":"33","author":"Peters","year":"2022","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2022.03.034_bib19","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1001\/jamaneurol.2016.1399","article-title":"Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer","volume":"73","author":"Williams","year":"2016","journal-title":"JAMA Neurol"},{"issue":"7","key":"10.1016\/j.ejca.2022.03.034_bib20","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMoa071780","article-title":"Prophylactic cranial irradiation in extensive small-cell lung cancer","volume":"357","author":"Slotman","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2022.03.034_bib21","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(17)30230-9","article-title":"Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2022.03.034_bib22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.1929","article-title":"Rates of overall survival and intracranial control in the magnetic resonance imaging era for patients with limited-stage small cell lung cancer with and without prophylactic cranial irradiation","volume":"3","author":"Pezzi","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.ejca.2022.03.034_bib23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.cllc.2016.06.012","article-title":"Effect of accurate staging using positron emission tomography on the outcomes of prophylactic cranial irradiation in patients with limited stage small-cell lung cancer","volume":"18","author":"Choi","year":"2017","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2022.03.034_bib24","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.ijrobp.2020.09.020","article-title":"Patterns of disease progression after carboplatin\/etoposide + atezolizumab in extensive-stage small-cell lung cancer (ES-SCLC)","volume":"108","author":"Higgins","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.ejca.2022.03.034_bib25","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2022.03.034_bib27","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijrobp.2012.12.025","article-title":"Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas","volume":"86","author":"Zeng","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.ejca.2022.03.034_bib28","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jtho.2018.01.012","article-title":"Safety of combined PD-1 pathway inhibition and intracranial radiation therapy in non\u2013small cell lung cancer","volume":"13","author":"Hubbeling","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"21","key":"10.1016\/j.ejca.2022.03.034_bib29","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study","volume":"38","author":"Rudin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.03.034_bib30","doi-asserted-by":"crossref","first-page":"v928","DOI":"10.1093\/annonc\/mdz394.089","article-title":"PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: results from CASPIAN","volume":"30","author":"Paz-Ares","year":"2019","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2022.03.034_bib31","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup Analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2022.03.034_bib35","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.03.034_bib36","doi-asserted-by":"crossref","first-page":"S1212","DOI":"10.1016\/j.annonc.2020.08.2328","article-title":"LBA86 Durvalumab (D) \u00b1 tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN","volume":"31","author":"Goldman","year":"2020","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922001824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922001824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:35:15Z","timestamp":1760733315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922001824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":32,"alternative-id":["S0959804922001824"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.03.034","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.03.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}